PMID- 26085897
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150618
LR  - 20200930
IS  - 1911-6470 (Print)
IS  - 1920-1214 (Electronic)
IS  - 1911-6470 (Linking)
VI  - 9
IP  - 3-4
DP  - 2015 Mar-Apr
TI  - Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma 
      (HLRCC): Case report and review of the literature.
PG  - E243-6
LID - 10.5489/cuaj.2264 [doi]
AB  - The overall survival for patients with advanced papillary renal carcinoma (RCC) 
      is still limited. Although multikinase inhibitors have recently been developed 
      for clear cell carcinoma, response rates in other histology non-clear cell RCC 
      are poor and patients often face dose-limiting toxicities which lead to a 
      reduction in prognosis and treatment success. We present a patient with 
      hereditary leiomyomatosis and RCC (HLRCC), showing a sustained response for more 
      than 12 months to gemcitabine-bevacizumab therapy after failure tyrosine kinase 
      inhibitors (TKIs) and mammalian target of rapamycin (mTOR) therapies.
FAU - de Velasco, Guillermo
AU  - de Velasco G
AD  - Department of Uro-Oncology, University Hospital 12 de Octubre, Madrid, Spain.
FAU - Munoz, Cesar
AU  - Munoz C
AD  - Department of Uro-Oncology, University Hospital 12 de Octubre, Madrid, Spain.
FAU - Sepulveda, Juan M
AU  - Sepulveda JM
AD  - Department of Uro-Oncology, University Hospital 12 de Octubre, Madrid, Spain.
FAU - Castellano, Daniel
AU  - Castellano D
AD  - Department of Uro-Oncology, University Hospital 12 de Octubre, Madrid, Spain.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Urol Assoc J
JT  - Canadian Urological Association journal = Journal de l'Association des urologues 
      du Canada
JID - 101312644
PMC - PMC4455657
EDAT- 2015/06/19 06:00
MHDA- 2015/06/19 06:01
PMCR- 2015/03/01
CRDT- 2015/06/19 06:00
PHST- 2015/06/19 06:00 [entrez]
PHST- 2015/06/19 06:00 [pubmed]
PHST- 2015/06/19 06:01 [medline]
PHST- 2015/03/01 00:00 [pmc-release]
AID - cuaj-3-4-e243 [pii]
AID - 10.5489/cuaj.2264 [doi]
PST - ppublish
SO  - Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6. doi: 10.5489/cuaj.2264.